<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83013">
  <stage>Registered</stage>
  <submitdate>25/07/2008</submitdate>
  <approvaldate>18/08/2008</approvaldate>
  <actrnumber>ACTRN12608000404325</actrnumber>
  <trial_identification>
    <studytitle>An Australian, phase II , multicentre, randomised, open-label, dose intensification study of three patient cohorts, investigating varying dose schedules, each of 6 x 28day cycles, with monitoring continuing for 12 months into the post treatment period.</studytitle>
    <scientifictitle>An Australian, phase II , multicentre, randomised, dose intensification study investigating oral fludarabine, oral cyclophosphamide, and intravenous rituximab (poFCivR) tolerance in previously untreated elderly (=65years old) patients with chronic lymphocytic leukaemia. (CLL)</scientifictitle>
    <utrn />
    <trialacronym>OFOCIR</trialacronym>
    <secondaryid>Australasian Leukaemia and Lymphoma Group: ALLG CLL5</secondaryid>
    <secondaryid>Australasian Leukaemia and Lymphoma Group</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Lymphocytic Leukaemia (CLL)</healthcondition>
    <healthcondition>Chronic Lymphocytic Leukaemia (CLL)</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>To investigate the safety and tolerability of  fludarabine,  cyclophosphamide, and  rituximab in previously untreated elderly (=65years old) patients with chronic lymphocytic leukaemia. (CLL).
Treatment Arm1:oral fludarabine 24 mg/m2 days 1-5. plus intravenous (i.v.) rituximab Cycle 1: 375 mg/m2 day 0*
Cycles 2-6: 500 mg/m2 day 1 (Fludarabine Rituximab:FR5), 
Treatment Arm2 and Arm3 :oral fludarabine 24 mg/m2 days 1-3. plus oral cyclophosphamide 150 mg/m2 days 1-3. in varing dose intensity with i.v. rituximab Cycle 1: 375 mg/m2 day 0*
Cycles 2-6: 500 mg/m2 day 1 (Fludarabine Cyclophosphamide Rituximab: FCR3 and Fludarabine Cyclophosphamide Rituximab FCR 5).
Dose schedule is determined via randomisation.
Duration is x6 28day cycles.
There is no wash out period between cycles.</interventions>
    <comparator>'There are three cohorts of active treatment. Randomisation arms allocated via randomisation (as described in the description of the interventions)'.</comparator>
    <control>Dose comparison</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The proportion of patients completing 6 treatment cycles</outcome>
      <timepoint>24 weeks (6 x 28 day cycles)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Rate of grade 4 haematological toxicities, as defined by National Cancer Institute Common Toxicity Criteria NCI-CTC Grading Scale for haematological toxicity for patients in this study. Documented in Protocol.</outcome>
      <timepoint>14 month follow-up (final staging 2 months post-treatment + 12 months follow-up)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rate of grade 3+ non-haematological toxicities as defined by NCI-CTC Grading Scale for haematological toxicity for patients in this study. Documented in Protocol.</outcome>
      <timepoint>14 month follow-up (final staging 2 months post-treatment + 12 months follow-up)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall response rate (ORR), Complete Response (CR), Complete Remission with incomplete marrow recovery (CRi), Nodular Partial Remission (nPR), Partial Remission (PR).</outcome>
      <timepoint>14 month follow-up (final staging 2 months post-treatment + 12 months follow-up)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Life (QoL)
European Organisation for Research and Treatment of Cancer EORTC QLQ-C30 questionnaire Version3.</outcome>
      <timepoint>14 month follow-up (final staging 2 months post-treatment + 12 months follow-up)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The proportion of responding patients at the end of the follow-up period. Those responding to treatment at the end of treatment.</outcome>
      <timepoint>14 month follow-up (final staging 2 months post-treatment + 12 months follow-up)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression-free survival (PFS), overall survival (OS)</outcome>
      <timepoint>14 month follow-up (final staging 2 months post-treatment + 12 months follow-up)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rate of treatment-related adverse events</outcome>
      <timepoint>14 month follow-up (final staging 2 months post-treatment + 12 months follow-up)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. B-CLL confirmed according to National Cancer Institute (NCI) Working Group Criteria.
2.  Binet stage B or C, or progressive symptomatic stage A (see Protocol Appendix I).
3.  Age = 65 years old.
4.  Judged to be in need of systemic therapy (see Protocol Appendix II).
5.  No previous treatment (chemotherapy, radiotherapy or immunotherapy) for CLL.
6.  Alkaline phosphatase and transaminases = 2 x ULN.(Upper Limits of Normal)
7.  Creatinine clearance = 50 ml/min (as calculated by (estimated Glomerular Filtration Rate) eGFR; eGFR also calculated by
Cockcroft and Gault formula for final analysis; see Protocol Appendix III).
8.  Females of childbearing potential or fertile males must take contraceptive measures during
and at least 6 months after cessation of therapy.
9.  (Eastern Cooperative Group) ECOG performance status 0-1.
10.  Cumulative Illnes Rating Scale CIRS score &lt; 6 (see Protocol Appendix IV).
11.  Life expectancy &gt; 6 months.
12.  Patients written informed consent.</inclusivecriteria>
    <inclusiveminage>65</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.  Age &lt; 65 years old.
2.  Non-progressive or stable Binet stage A.
3.  Clinically significant auto-immune cytopenia, Coombs-positive haemolytic anaemia (as
discerned by treating physician).
4. Active second malignancy currently requiring treatment (except for non-melanoma skin
cancer or cervical cancer in situ or tumour treated curatively by surgery &gt; 5 years ago) 
5.  Concomitant disease requiring prolonged use of glucocorticoids (&gt; 1 month).
6.  Known hypersensitivity with anaphylactic reaction to humanised monoclonal antibodies or
any of the study drugs.
7.  ECOG performance status 2-3.
8.  Class III or IV cardiac disease defined by the NYHA.
9.  Severe or debilitating pulmonary disease.
10. Severe or debilitating central nervous system disease or cerebral dysfunction.
11. Transformation to aggressive B-cell malignancy, e.g. diffuse large cell lymphoma, Richters
syndrome or prolymphocytic leukaemia.
12.  Active bacterial, viral or fungal infection; patients who have known Human Immunodeficiency
Virus (HIV) infection or active hepatitis B virus (HBV) or hepatitis C virus
(HCV) infection.
13. Total bilirubin &gt; 2 x ULN.
14. Creatinine clearance &lt; 50 ml/min (as calculated by eGFR).
15.  Any coexisting medical or psychological condition that would preclude participation in the
required study procedures.
16.  Treatment with any other investigational agent, or participation in another clinical trial
within 30 days prior to entering this study.
17.  Pregnancy and lactation.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>central randomisation by phone /fax /computer</concealment>
    <sequence>Simple randomisation by using a randomization table created by a computer software (i.e., computerised sequence generation)</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/08/2008</anticipatedstartdate>
    <actualstartdate>10/12/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate>31/05/2010</actualenddate>
    <samplesize>120</samplesize>
    <actualsamplesize>120</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>31/12/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC,QLD,SA,WA,NT,TAS</recruitmentstate>
    <hospital>Austin Health - Austin Hospital - Heidelberg</hospital>
    <hospital>Border Medical Oncology - Wodonga</hospital>
    <hospital>The Canberra Hospital - Garran</hospital>
    <hospital>Coffs Harbour Base Hospital - Coffs Harbour</hospital>
    <hospital>Concord Repatriation Hospital - Concord</hospital>
    <hospital>Flinders Medical Centre - Bedford Park</hospital>
    <hospital>Frankston Hospital - Frankston</hospital>
    <hospital>Gold Coast Hospital - Southport</hospital>
    <hospital>Barwon Health - Geelong Hospital campus - Geelong</hospital>
    <hospital>Gosford Hospital - Gosford</hospital>
    <hospital>Royal Hobart Hospital - Hobart</hospital>
    <hospital>Launceston General Hospital - Launceston</hospital>
    <hospital>Monash Medical Centre - Clayton campus - Clayton</hospital>
    <hospital>Mater Misericordiae Hospital Bundaberg - Bundaberg</hospital>
    <hospital>Port Macquarie Private Hospital - Port Macquarie</hospital>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <hospital>Peter MacCallum Cancer Centre - Melbourne</hospital>
    <hospital>The Queen Elizabeth Hospital - Woodville</hospital>
    <hospital>Royal Darwin Hospital - Tiwi</hospital>
    <hospital>Royal Melbourne Hospital - City campus - Parkville</hospital>
    <hospital>Royal North Shore Hospital - St Leonards</hospital>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <hospital>St George Hospital - Kogarah</hospital>
    <hospital>St Vincent's Hospital (Melbourne) Ltd - Fitzroy</hospital>
    <hospital>Westmead Hospital - Westmead</hospital>
    <hospital>Wollongong Hospital - Wollongong</hospital>
    <postcode>3084 - Heidelberg</postcode>
    <postcode>3690 - Wodonga</postcode>
    <postcode>2605 - Garran</postcode>
    <postcode>2450 - Coffs Harbour</postcode>
    <postcode>2139 - Concord</postcode>
    <postcode>5042 - Bedford Park</postcode>
    <postcode>3199 - Frankston</postcode>
    <postcode>4215 - Southport</postcode>
    <postcode>3220 - Geelong</postcode>
    <postcode>2250 - Gosford</postcode>
    <postcode>7000 - Hobart</postcode>
    <postcode>7250 - Launceston</postcode>
    <postcode>3168 - Clayton</postcode>
    <postcode>4670 - Bundaberg</postcode>
    <postcode>2444 - Port Macquarie</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>3000 - Melbourne</postcode>
    <postcode>5011 - Woodville</postcode>
    <postcode>0810 - Tiwi</postcode>
    <postcode>3050 - Parkville</postcode>
    <postcode>2065 - St Leonards</postcode>
    <postcode>6009 - Nedlands</postcode>
    <postcode>2217 - Kogarah</postcode>
    <postcode>3065 - Fitzroy</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>2500 - Wollongong</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>Australasian Leukaemia and Lymphoma Group</primarysponsorname>
    <primarysponsoraddress>Level 2, 10 St Andrews Place, East Melbourne 3001 Victoria</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Roche</fundingname>
      <fundingaddress>Roche Australia,81-89 Cotham Road Kew 3101 Victoria</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Bayer</fundingname>
      <fundingaddress>Bayer Australia, 875 Pacific Hwy Pymble 2073 New South Wales</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The trial is a randomised phase II open-label multicentre trial investigating oral fludarabine, cyclophosphamide and intravenous rituximab in previously untreated elderly (= 65 years old) patients with chronic lymphocytic leukaemia. The primary objective is to investigate the tolerability of each of three of these combination chemotherapies and the associated primary endpoint is the proportion of paitens able to complete 6 cycles of therapy.</summary>
    <trialwebsite>www.petermac.org/allg</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern Sydney Central Coast Health</ethicname>
      <ethicaddress>Level 4, Vindin House, Royal North Shore Hospital, NSW 2065</ethicaddress>
      <ethicapprovaldate>19/09/2008</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>18/06/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Stephen Mulligan </name>
      <address>Department of Haematology, Royal North Shore Hospital. St Leonards, Sydney. NSW 2065</address>
      <phone>02-9926 7601</phone>
      <fax>02-9906 1635</fax>
      <email>mulligan@staff.usyd.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Stephen Mulligan</name>
      <address>Department of Haematology, Royal North Shore Hospital. St Leonards, Sydney. NSW 2065</address>
      <phone>02-9926 7601</phone>
      <fax>02-9906 1635</fax>
      <email>mulligan@staff.usyd.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Delaine Smith, ALLG</name>
      <address>Ground Floor, 35 Elizabeth Street, Richmond, VIC 3121</address>
      <phone>+61 3 8373 9701</phone>
      <fax />
      <email>delaine.smith@allg.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Stephen Mulligan</name>
      <address>Department of Haematology, Royal North Shore Hospital, St. Leonards, Sydney, NSW 2065U</address>
      <phone>0299267601</phone>
      <fax />
      <email>mulligan@staff.usyd.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>